Suchergebnisse

Coronavirus disease 2019 (COVID-19) has become a major, global, public health challenge. More than 1,051,635 confirmed cases (and counting) have been reported worldwide, thus far, and both local and international travelers are considered to represent populations at high risk of acquiring the infection. Many factors are involved in the spread of this viral agent, including travel to and from endemic areas, a history of contact with a traveler from an endemic country, the virus infection rate at the destination, individual health, and inadequate prevention and control measures. COVID-19 symptoms range from fever and cough to difficulty breathing, and more severe cases can present with pneumonia and multi-organ failure. The virus is thought to be transmitted through large respiratory droplets, generated by coughing or sneezing and transmitted through close contact with infected persons or contaminated surfaces. Diagnostic strategies include the assays for the detection of antiviral antibodies, multiplex nucleic acid amplification, and microarray-based assays. Currently, no approved antiviral therapy or vaccine exists to treat or prevent the infection. Public health measures, such as quarantine, have been enforced, to slow the community spread of the virus, by governments, worldwide. The World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) have recommended COVID-19 infection screening be performed at airports, for all travelers, before traveling to endemic countries and the restriction of travel to countries more than one thousand cases of infection. In response to the global outbreak, this review examines COVID-19 as a potential traveler's infection.

Objective: Neuropathic pain and fibromyalgia are two common and poorly understood chronic pain conditions that lack satisfactory treatments, cause substantial suffering and societal costs. Today, there are no biological markers on which to base chronic pain diagnoses, treatment choices or to understand the pathophysiology of pain for the individual patient. This study aimed to investigate cerebrospinal fluid (CSF) protein profiles potentially associated with fibromyalgia and neuropathic pain. Methods: CSF samples were collected from 25 patients with neuropathic pain (two independent sets, n=14 patients for discovery, and n=11 for verification), 40 patients with fibromyalgia and 134 controls without neurological disease from two different populations. CSF protein profiling of 55 proteins was performed using antibody suspension bead array technology. Results: We found increased levels of apolipoprotein C1 (APOC1) in CSF of neuropathic pain patients compared to controls and there was a trend for increased levels also in fibromyalgia patients. In addition, levels of ectonucleotide pyrophosphatase family member 2 (ENPP2, also referred to as autotaxin) were increased in the CSF of fibromyalgia patients compared to all other groups including patients with neuropathic pain. Conclusion: The increased levels of APOC1 and ENPP2 found in neuropathic pain and fibromyalgia patients may shed light on the underlying mechanisms of these conditions. Further investigation is required to elucidate their role in maintaining pain and other main symptoms of these disorders. ; Funding Agencies|Swedish Governmental Agency for Innovation SystemsVinnova; Swedish Research Council (Vetenskapsradet)Swedish Research Council; Uppsala University; KTH Center for Applied Precision Medicine (KCAP); Marie-Curie fellowship from the INSENS/FP7-PEOPLE-2013European Union (EU) [607616]; NEURO Sweden; AFA Insurance; ALF Grants, Region Ostergotland